Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of intra-operative Onabotunlinumtoxin-A for management of bladder reconstruction by reducing post-operative narcotic and anticholinergic requirements in children undergoing bladder reconstruction

Trial Profile

Efficacy of intra-operative Onabotunlinumtoxin-A for management of bladder reconstruction by reducing post-operative narcotic and anticholinergic requirements in children undergoing bladder reconstruction

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Neurogenic bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2018 New trial record
    • 02 May 2018 Primary endpoint of narcotic and anticholinergic requirements has been met, according to results published in the Urology.
    • 02 May 2018 Results published in the Urology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top